The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Https://www.sec.gov/Archives/edgar/data/1896212/000149315223045267/form424b3.htm
Https://www.londonstockexchange.com/news-article/EISB/appointment-of-allenby-capital-as-broker/16243761
RNS Number : 1008W
East Imperial PLC
08 December 2023
8 December 2023
East Imperial plc
(the "Company")
Appointment of Allenby Capital as Broker
East Imperial plc, the global purveyor of super-premium beverages, is pleased to announce the appointment of Allenby Capital Limited as the Company's sole Broker, with immediate effect.
The appointment aligns with the Company's strategy of expanding the group's investor base as it continues to establish itself as the producer of super-premium beverages across APAC, the US and EMEA.
Tony Burt, Chairman, Founder and CEO of East Imperial, said:
"We are very pleased to be embarking on a long-term partnership with Allenby Capital as our Broker. They deeply understand the consumer retail and hospitality sector, particularly within the growth company space. Their experience in helping ambitious companies grow will be invaluable to East Imperial as we expand in premium markets worldwide. This is an important milestone in our strategy to become the most admired premium brand of mixers and drive sustainable growth to create value for our shareholders."
Allenby Capital is a leading corporate adviser and broker advising over 70 corporate clients on the London Stock Exchange Main Market, AIM or Aquis exchanges. Based in London, it is employee owned and focuses on the small cap and growth company sectors, having a strong history of supporting the capital markets of its extensive client base.
Honestly Jace it cracks me up. People can put whatever checkout price they want on this, thats personal, but to tjhink Dr Dawn Coverley has been at this for over 15 years, and would be willing to sell out at 5 times RTO price? LOL
Like you mate here for the end game and that is far in excess to what others consider. Made my day! LOL
Today 07:00
RNS Number : 2956T
Oxford Cannabinoid Tech.Holdings
14 November 2023
Oxford Cannabinoid Technologies Holdings plc
("OCTP" or the "Company")
Directorate Appointment
Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP), the pharmaceutical company developing prescription cannabinoid medicines, announces the following Board appointment.
Reflecting his exceptional experience and valued contribution to the progress of OCTP, the Company is pleased to announce the appointment of Dr Tim Corn, Chief Medical Officer ("CMO"), as an executive director, effective immediately. As announced on 8 June 2023, Dr Corn joined OCTP as CMO to oversee the Company's clinical research and development activities as well as to provide expert medical guidance and advice to the team. Since joining, the Company has successfully completed its first Phase I clinical trial, a single ascending dose study of its lead compound OCT461201.
Dr Corn, formerly Chief Medical Officer International at Jazz Pharmaceuticals plc, has played a key role in the successful conclusion of more than twenty regulatory approvals in the US and Europe and is the author of more than forty scientific publications. He was elected Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists.
13 November 2023
East Imperial plc
(the "Company")
Directorship Changes
East Imperial plc, the global purveyor of ultra-premium beverages, today announces that Alistair McGeorge will step down as Chairman and Non-Executive Director of the Company, effective 10 November 2023.
Robin Stevens will join as a Non-Executive Director effective 10 November 2023. Robin brings a wealth of experience in corporate finance, financial advisory and business consulting. Currently, he is a Senior Adviser and Capital Markets Lead at MHA MacIntyre Hudson LLP, providing capital markets and corporate finance advice to firms in the UK and overseas. He has particular experience working with emerging companies in the Asia-Pacific region.
CEO and Founder Tony Burt will act as Executive Chairman until an independent Chair with the appropriate industry expertise has been identified and appointed.
Tony Burt, CEO/Founder, commented:
"I'd like to thank Alistair for his two years of service and wish him all the best for the future. I'm also delighted to welcome Robin, who brings extensive experience in corporate finance, PLC governance and emerging companies in the Asia-Pacific region. His knowledge of the City, insight and UK PLC experience will be a tremendous asset to us."
7:05 AM · Oct 31, 2023
Pullman Hotel Singapore
https://twitter.com/East_Imperial/status/1719249253824901564
(part 3)
For example I do know that Supermarkets are CONSTANTLY vying with one another even stores from within the same company. Notably, one NZ Supermarket stocks EISB then another follows suit. In the 2022 Annual Report: “Foodstuffs, New Zealand’s largest food retailer, extended our placement across 102 North Island stores. With this, we are now found in all New Worlds and their competitors, Countdown (110 stores), across the country.”
7. My final key assumption is margin. I assume we see 20% margin (i.e. the same as H1’s adjusted margin, i.e. no more written off stock), followed by 32% in 2024 (WH Ireland’s estimate) when “Management believes over time that a goal of a margin above 45% is achievable for a super-premium product.”
Investment Thesis
Should you invest? I don’t give advice. But giving myself some advice I’m happy to continue to hold here. Extremely happy I topped up and averaged down at 0.9p because I’m now back in profit. Will it survive its rocky past 12 months? - my numbers appear to say yes. Will there be dilution - again yes - but the nature of the scheme means as the share price rises the dilution diminishes. Currently it equates to about 10% dilution, which I’m more than happy with.
Could EISB be the next Fevertree? When you extrapolate to FY2025 things get very exciting. When you hit 45% margins, not 32% this becomes very profitable. Applying a 30X valuation to the FY2024 H2 adjusted profit arrives at a target value of £45m which is 5X today’s market cap. Doubling again in 2025 and applying 30X arrives at a 10 bagger - just like Fevertree.
A final thought:
Do you want to see East Imperial being sold online? Click here if you do
A Kiwi Dollar is $1 = £0.49 so a 10 pack is about £11 or £6.11 a litre.
Fevertree in Sainsburys is £8.25 and £4.71a litre.
So East Imperial is 25% more expensive. But award winning.
What about the Peter Lynch test…. only buy what you know. So it passes. I would pay extra for something that tasted that much nicer. Ironically, with Fevertree’s ditty of “when the tonic is 80% of the drink….” echoing in my head!
Have a great weekend reader, and thank you for reading the latest thoughts from the Oak Bloke.
(part2)
macau.
“with the strategic investment from inl investments, we will see a renewed focus on growing our position in china as the super-premium mixer for this market. the focus for q4 and q1 2024 will be macau, focusing on luxury accommodation and exquisite dining experiences to which our products are well suited.”
pre-covid there were 39m tourists a year spending us$40bn a year. while there are not macau alcohol statistics broadly in china spirits consumption is enormous worth us$166bn/year
so the “asian las vegas” where people go to have a great time, seems a great way to focus on growing sales.
forecasts:
key asumptions: (i’ve used the interim report and the 2022 annual report to obtain numbers)
1. i’ve calculated the price per case in 2021 was £13.51 and 2022 was £14.02. i’m using £14.02 for 2023 and 2024. this might be conservative. while case sales are not disclosed in the interims, i estimate at 89,642 cases for h1 2023 which is 22% less than 2022.
2. i’ve calculated the cost per case in 2021 was £10.91 and 2022 was £11.83. adjusted cost per case in h1 2023 i estimate at £11.76 which is highly consistent to h2 2022.
3. i’m conservatively assuming overheads are static despite eisb saying we “anticipate further efficiencies to help drive a lower operating cost base, including an incentive program tightly aligned to broader business targets”. tightly aligned means you get great commission but don’t expect a base salary bump :)
4. i’m not making any assumptions around other income, fx, just focused on operational outcome.
5. i’m assuming receivables remain low in h2 (i previously commented that they would run a tight ship on receivables) but inevitably rise next year. charging for fob basically means the money is due when it reaches the ship, not when it reaches the customer.
6. sales - i’m conservatively assuming +40% in h2 (89,642 cases) at £14.02/case. i’m doubling volumes in h1 2024 and doubling again in h2. this is a key assumption. but that equates to an additional 125k cases in h1 2024 and 250k cases in h2. with 12 bottles per case that’s equivalent to 1% in h1 then 2% in h2 of macau tourists enjoying just 4 bottles of east imperial mixers during a holiday. or the 1m ****tail courier recipients receiving 1 bottle each plus 0.4% then order a case in h1 and just a quarter of that 0.4% go on to order a case a week in h2 “coz, boss, yeah, this stuff is selling like hot cakes - and, yeah, let’s talk now about that tightly aligned incentive scheme we was talking about”. or air new zealand selling a single bottle to 1% of its 17m annual passengers and of those a third go on to buy a few cases. or some combination of the above plus everything else which is going on.
(cont'd)
the oak bloke
1 oct 2023
i don’t generally get interested in business2consumer (b2c) shares.
but we all know the story of fevertree - and the fact that it’s 9 bagged since its ipo (£1.4bn vs £154m)
eisb holds some intriguing similarities.
1. air new zealand. okay, not quite british airways, but eisb have secured a deal to supply 1st class passengers - just like fevertree did with ba all those years ago.
2. award winning - a smattering of 9 silver and gold from the spirits and mixer masters - the tonics get a very positive write up in the spirits business with its “tangy and tart yuzu” on the palate and ginger beer “this authenticity followed through from the aroma to the flavour profile, securing the top award”
****tail courier
“east imperial become the official mixer in their ****tail kits delivered to over 1,000,000 us homes, is a testament to jaron's business development capabilities and the power of our brand versus other players in the us market. management believes that having east imperial in the hands of this audience will drive both trial and sales.”
this appears to be a bit of a coup. ****tail courier has been going nearly 10 years and is a “go to” if ****tails are your thing
typically, its readership and members are a/ high net worth people and wannabes trying to outdo each other - think people with their home bar or garden bar - plus bar tenders. think about that last bit. this publication is read by people who make the drinks in bars and hotels, and buy in the supplies. can you picture a bar tender from new jersey saying “hey boss, i’ve got a great idea, there’s a great new super premium tonic, and it’s all the rage. customers will love it and the margins are fantastic.”
and that’s why it’s a coup. (cont'd)
I get very worried when someone like Charles Archer goes to such lengths to write and then make a massive error. He kept referring to CIZ being on AIM or an AIM Biotech. That is basics and they got that wrong. If the reply is that its the same thing regardless, then that is not right either.
Https://www.londonstockexchange.com/news-article/OCTP/final-dose-administered/16137098
DvHarrison amd Ishty, this is not an AIM stock so hopefully that is cleared up. Secondly you made your posts literally 10 minutes into the market opening, so thats a bit worrying if you have concerns about CIZ not runing up immediately from the start. I am suprised your post got 5 people recommending!!
Great day for those who have held for the long term and remain tight gripped to their holdings.
There are 960m ordinary shares with a nominal face value of 1p. The proposal is to reclassify the nominal shares as 960m at 0.1p nominal face value and to create 960m new deferred shares at 0.9p face value. To be more precise:
960,415,644 Redenominated Ordinary Shares each with a nominal value of 0.1 pence
960,415,644 Deferred Shares each with a nominal value of 0.9 pence.
subject to the passing of resolutions 8, 9 and 13.
If this happens then the Deferred shares can be reissued as new ordinary shares up to a value of £320.138.55. (Basically, the company can then issue new issues shares to raise new capital if needed.)
Your shareholding remains the same, only the face nominal value has changed from 1p to 0.1p, (not the market price of the shares) and the company has authorisation to raise capital up to the value representing one third of the Company’s issued Redenominated Ordinary Shares at that time, whether it be rights issue or whatever other means.
Though FEVR results today showed EPS down 90% from 12p to 1.2p, gross profits and also gross margins down, they have shown a rise of 40% on US revenue margins based on this year compared to last year.
EISB in a total different area of serving a premium brand through exclusive outlets and venues, it will be very interesting to see what the USA figures are going to be like. We could honestly be very undervalued here, now finances are secured to see us through to next year.
Today 08:13
RNS Number : 5523L
East Imperial PLC
06 September 2023
6 September 2023
East Imperial plc
(the "Company")
Directorship Changes
East Imperial plc, the global purveyor of ultra-premium beverages, today announces that Colin Henry and Toby Hayward will step down as Non-Executive Directors of the Company, effective 1 September 2023.
Horace Ngai will join as a Non-Executive Director effective 5 September 2023, appointed to the Company's strategic advisory board in October 2021. Horace began his career at Procter and Gamble in China (1991-2000), during which he was one of the first marketing pioneers for the company, building the success of its haircare & beauty care brands. Between 2000 and 2018, he held various senior management positions at Pernod Ricard across Asia, including Senior President of Pernod Ricard in China.Horace was also the CEO of Sichuan Shui Jing Fang Co. Ltd, a listed company on the Shanghai Stock Exchange majority-owned by Diageo, between 2019 and 2020. Horace is a representative of INL Investments, a distributor of East Imperial products and a recent investor in the Company.
Alistair McGeorge will remain as Chair until a suitable replacement with the appropriate industry expertise can be found. Alistair will assume the role of chairing the Audit and Remuneration Committees.
Alistair McGeorge, Chairman, commented:
"I would like to thank Colin and Toby for their contribution to the Board and wish them both well with their next endeavours. The changes to East Imperial reflect a recalibration of the cost structures and the desire for governance support to include an appropriate level of industry expertise. In that regard, I welcome Horace to the board."
Tony Burt, CEO/Founder, commented:
"I'd like to thank Colin and Toby and wish them all the best for the future. I'd also like to welcome Horace, who brings extensive experience in the premium drinks industry in Asia. His insight and experience will be a huge asset as we work closely with our new investment partner, INL Investments, in that region."
Https://twitter.com/OxCanTech/status/1691705693110186300
AI is essential for the future of drug discovery & development
“incorporating #ArtificialInteligence into drug discovery and development has the potential to revolutionise both patient experiences and outcomes”
East Imperial - Premium Tonic Waters & Mixers
@East_Imperial
·
14m
Pleased to receive confirmation today that #EastImperial will now be served throughout the InterContinental Bellevue in Seattle. It’s such an honour to work with IHG and another great win for the team. More to follow